BTIG lowered the firm’s price target on Organogenesis (ORGO) to $8 from $9 and keeps a Buy rating on the shares. The company reported a blowout quarter, but its FY26 guidance reflects a “new economic reality”, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO: